Free Newsletter
Stanford nixes industry-funded CME
The church-and-state separation of drugmakers and continuing medical education continues apace. Now it's Stanford's medical school that's refusing to take industry funding for specific CME programs or courses. The school won't accept money or in-kind help like equipment or supplies or services. Nor will it let for-profit CME companies that take industry money deliver their courses on campus.
Stanford joins a handful of other institutions that have curtailed their industry-funded CME recently. Memorial Sloan-Kettering cut itself off of industry funding for CME, the Wall Street Journal Health Blog reminds us, and Pfizer recently came at the problem from a different direction by saying it would no longer fund CME courses offered by for-profit companies.
What will Stanford accept? Well, it will take contributions to a pool of money that the university can then allocate as it sees fit. About half a dozen other med schools have created similar pools. It's an idea that could catch on; in fact, the CME accreditation body has been considering establishing a centralized pool for industry contributions. The money would be divvied up by medical societies.
- read the WSJ Health Blog post
- see the New York Times story
Related Articles:
AMA won't ban industry-funded education
Arms twisted, pharma promises CME disclosure
Med schools tight with drugmakers
GSK to report organization grants
Pfizer to stop funding for-profit CME
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: